SPOTLIGHT: Amgen, Roche square off


Amgen and Roche head into court today to continue their fight over anemia drugs. Roche wants to market Mircera, its treatment for the malady, but Amgen claims the drug violates Amgen patents. Last week, Roche thumbed its nose at Amgen, saying it will sell Mircera as soon as the FDA gives its OK--whether Amgen likes it or not. We'll see whether the court has other ideas. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.